Results 61 to 70 of about 11,189 (206)
Therapeutic Effects of Bromocriptine in Idiopathic Parkinsonism [PDF]
, 1984 Therapeutic eκects of bromocriptine were evaluated in 16 idiopathic Parkinsonism patients. 22.5mg of bromocriptine was added to the conventional antiparkinsonian agents including L-dopa, and clinical evaluation was performed according to the ...
이문규, 민헌기, 이상복
core
Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia [PDF]
Journal of Clinical and Diagnostic Research, 2013 Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like ...
Harish Kumar V.S. +5 more
doaj +1 more source
Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan +10 more
wiley +1 more source
Acta Medica Indonesiana, 2023 Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advanced-stage breast cancer is often harder as a result of chemoresistance.
Muhammad Yadi Permana +2 more
doaj +2 more sources
British Journal of Pharmacology, Volume 183, Issue 10, Page 2518-2532, May 2026.Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki +4 more
wiley +1 more source
Reversible cerebral vasoconstriction syndrome: A narrative review
Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1162-1180, May 2026.Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa +7 more
wiley +1 more source
Bromocriptine in the Rett syndrome. [PDF]
, 1990 Twelve typical cases of the Rett syndrome and one forme fruste were treated with bromocriptine for six months and then had a washout for two months followed by resumption of the bromocriptine treatment. During the first bromocriptine treatment there were
M. Zappella +3 more
core
DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut
Advanced Science, Volume 13, Issue 24, 27 April 2026.Dopamine receptor D2 (DRD2) deficiency disrupts epithelial barrier integrity in both the gut and pituitary gland, facilitating translocation of gut‐derived Escherichia coli into pituitary tissue. Intratumoral E. coli are phagocytosed by microglia, triggering GSDMD‐dependent pyroptosis and HMGB1 release, which subsequently activates MAPK signaling to ...
Xian‐jun Su +16 more
wiley +1 more source
Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154). [PDF]
, 1978 Bromocriptine produces long-lasting hypomotility and decreases brain dihydroxyphenylacetic acid (DOPAC) in mice. These effects are obtained with doses much lower than those which produce hypermotility.
DI CHIARA, GAETANO +3 more
core +1 more source
Arthritis &Rheumatology, Volume 78, Issue 4, Page 985-992, April 2026.Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source